Pregnane steroids and their use in the treatment of CNS disorders
AssigneeUmecrine AB
InventorsTorbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
Life of this patent
Estimating the term…
Abstract
Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
Claims19
A method for the treatment or alleviation of 3alpha-hydroxy-5alpha/beta-steroid induced central nervous system (“CNS”) disorders in human patients, wherein at least one compound selected from the group consisting of 3beta,20alpha-dihydroxy-5beta-pregnane, 3beta,20alpha-dihydroxy-5beta-pregnane, 3beta,21-dihydroxy-5beta-pregnan-20-one, 3beta-hydroxy-5alpha-pregnan-11,20-dione, and 3beta-hydroxy-5alpha-pregnan-20-one-acetate, is administered to said human patient.
A method for controlling and/or terminating steroid anesthesia in human patients comprising administering to a patient in need thereof at least one compound selected from the group consisting of 3beta,21-dihydroxy-5beta-pregnan-20-one, 3beta-hydroxy-5alpha-pregnan-11,20-dione, and 3beta-hydroxy-5alpha-pregnan-20-one-acetate.
Dependencies are inferred from the claim text.